๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Reply: Plasma cholesterol and Parkinson's disease: Is the puzzle only apparent?

โœ Scribed by Xuemei Huang; Honglei Chen; Helen Petrovitch; Richard Mailman; Webster Ross


Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
88 KB
Volume
25
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

โœฆ Synopsis


I read with great interest the article by Alvarez et al. 1 In their review, they confirmed that Painful Legs and Moving Toes (PLMT's) etiology is diverse although the majority of patients had evidence of peripheral nerve involvement or radiculopathy. However, in some patients, namely in patients with Wilson's disease 2 and myelitis, 3 a structural central nervous system lesion is evoked to be associated with the development of PLMT. We reported a patient with Hashimoto's disease 4 who developed slight dystonia and bradykinesia and presented PLMT. The patient had any electrophysiological signs of neuropathy or any clinical sign indicative of a root or nerve disorder. MRI brain scan showed several small subcortical white matter fronto-parietal lesions, without diffusion restriction. Discrete and diffuse high signal in periventricular white matter was visible in T2-weighted images. These aspects are frequently found in Hashimoto's encephalopathy. 5 We also believe that at least in some cases PLMT has a central origin and is composed of a variety of dystonic movements. In our reported case, 4 we think PLMT was associated with Hashimoto's encephalopathy.


๐Ÿ“œ SIMILAR VOLUMES


Reply: The variability of levodopa respo
โœ Elena Moro; Panida Piboolnurak; Anthony E. Lang; Andres M. Lozano; Janis M. Miya ๐Ÿ“‚ Article ๐Ÿ“… 2008 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 27 KB ๐Ÿ‘ 1 views

We thank Dr. Jabre and his colleagues for their comments concerning our article 1 and the reduction of the levodopa response after bilateral subthalamic nucleus (STN) deep brain stimulation (DBS) in the long-term follow-up. We also agree that this partial loss of the levodopa clinical benefit after